CA3255932A1 - ACTIVE COMPOUNDS AGAINST BROMODOMAINS - Google Patents
ACTIVE COMPOUNDS AGAINST BROMODOMAINSInfo
- Publication number
- CA3255932A1 CA3255932A1 CA3255932A CA3255932A CA3255932A1 CA 3255932 A1 CA3255932 A1 CA 3255932A1 CA 3255932 A CA3255932 A CA 3255932A CA 3255932 A CA3255932 A CA 3255932A CA 3255932 A1 CA3255932 A1 CA 3255932A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyridine
- dihydrofuro
- quinolin
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2250473-2 | 2022-04-19 | ||
| SE2250473 | 2022-04-19 | ||
| PCT/US2023/019121 WO2023205251A1 (en) | 2022-04-19 | 2023-04-19 | Compounds active towards bromodomains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3255932A1 true CA3255932A1 (en) | 2023-10-26 |
Family
ID=86331094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3255932A Pending CA3255932A1 (en) | 2022-04-19 | 2023-04-19 | ACTIVE COMPOUNDS AGAINST BROMODOMAINS |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250382308A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511119B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025514712A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119365455A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023255396A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255932A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013002A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023205251A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2010317096B2 (en) | 2009-11-05 | 2015-03-26 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CA2779355C (en) | 2009-11-05 | 2018-01-16 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| HK1211033A1 (en) | 2012-12-20 | 2016-05-13 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroquinoxalinones |
| JP2016504990A (ja) | 2012-12-20 | 2016-02-18 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン |
| SG10201900631TA (en) * | 2014-08-01 | 2019-02-27 | Nuevolution As | Compounds active towards bromodomains |
| EP3563851B1 (en) * | 2016-12-27 | 2021-04-21 | FUJIFILM Corporation | Antitumor agent and bromodomain inhibitor |
-
2023
- 2023-04-19 CA CA3255932A patent/CA3255932A1/en active Pending
- 2023-04-19 JP JP2024560880A patent/JP2025514712A/ja active Pending
- 2023-04-19 US US18/860,589 patent/US20250382308A1/en active Pending
- 2023-04-19 EP EP23723033.9A patent/EP4511119B1/en active Active
- 2023-04-19 CN CN202380043848.XA patent/CN119365455A/zh active Pending
- 2023-04-19 AU AU2023255396A patent/AU2023255396A1/en active Pending
- 2023-04-19 WO PCT/US2023/019121 patent/WO2023205251A1/en not_active Ceased
-
2024
- 2024-10-21 MX MX2024013002A patent/MX2024013002A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025514712A (ja) | 2025-05-09 |
| CN119365455A (zh) | 2025-01-24 |
| EP4511119A1 (en) | 2025-02-26 |
| WO2023205251A1 (en) | 2023-10-26 |
| EP4511119B1 (en) | 2026-07-15 |
| US20250382308A1 (en) | 2025-12-18 |
| AU2023255396A1 (en) | 2024-10-24 |
| MX2024013002A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023325128A1 (en) | Kras inhibitors | |
| KR20250070059A (ko) | 신규한 테트라헤테로사이클 화합물 | |
| CN117957226A (zh) | 作为sos1抑制剂的杂环化合物及其用途 | |
| AU2020232026A1 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
| US8722661B2 (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | |
| TWI601718B (zh) | 2-arylaminopyridines, pyrimidine or triazine derivatives, processes for preparing the same, and uses thereof | |
| JP2022523981A (ja) | 抗癌剤として有用な縮合三環式化合物 | |
| EP3573987A1 (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| MX2014008605A (es) | Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo. | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| CN115867346B (zh) | 激酶抑制剂 | |
| KR20200101389A (ko) | 메닌-mll 상호작용의 엑소-아자 스피로 억제제 | |
| AU2019237991B2 (en) | JAK inhibitors | |
| AU2020386189B2 (en) | Adenosine receptor antagonist compounds | |
| CN106188038A (zh) | 一类具有激酶抑制活性的化合物、制备方法和用途 | |
| EP4161657A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
| AU2021373162A1 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| CN109721600A (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
| CN117126136B (zh) | Parp7抑制剂及其应用 | |
| CN121443595A (zh) | 用于治疗自身免疫性疾病的大环化合物 | |
| EP4511119A1 (en) | Compounds active towards bromodomains | |
| EP3028703B1 (en) | Piperidine derivatives as wnt signaling inhibitor | |
| WO2023139536A1 (en) | (4-piperazin-1yl)-4-alkyl-phthalazin-1(2h)-one compounds as parp7 inhibitors | |
| CN112047932A (zh) | 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途 | |
| WO2025151478A1 (en) | Compounds and composition for targeting tp53-y220c mutants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241015 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250127 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250127 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250127 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250401 |